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Introduction: Fifteen to sixty percent of cystic ﬁbrosis patients harbor Aspergillus fumigatus (Af) in their airways (CF-AC) and some will develop
allergic bronchopulmonary aspergillosis (CF-ABPA). Since basophils play a key role in allergy, we hypothesized that they would display
alterations in CF-ABPA patients compared to CF-AC or patients without Af colonization (CF).
Methods: Using ﬂow cytometry, we measured CD203c, CD63 and CD123 levels on basophils from CF-ABPA (N=11), CF-AC (N=14), and CF
(N=12) patients before and after ex vivo stimulation with Af allergens.
Results: Baseline CD203c was increased in basophils from CF-ABPA compared to CF-AC and CF patients. Af extract and recombinant Aspf1
stimulated basophils from CF-ABPA patients to markedly upregulate CD203c, along with modest upregulation of CD63 and a CD123 downward
trend. Plasma TARC/CCL17 at baseline and post-stimulation cell supernatant histamine levels were similar in the three groups.
Conclusions: In CF-ABPA, blood basophils are primed and hyperresponsive to Af allergen stimulation.
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Most of the morbidity and mortality among cystic fibrosis (CF)
patients is associated with airway disease [1]. CF airway disease,
which starts soon after birth, results in airway obstruction caused
by a pathological triad of inspissated mucus, inflammation (mostly
with neutrophils) [2], and microbial colonization. Although the
prokaryotic bacteria P. aeruginosa and S. aureus are the dominant
microorganisms in CF [3], a large proportion of CF patients also
harbor the eukaryotic filamentous fungus Aspergillus fumigatus
(Af) [4–6].
The relationship between host and Af in CF is quite complex
[7]. Some CF patients show stable Af colonization (CF-AC), whichby Elsevier B.V. All rights reserved.
Table 1
Characteristics of the patients enrolled in this study.
Group Sex Age Genotype Af MPA PA SA ITRA OS ZIT TOBI IgE
(Ku/L)
FEV1 in L.
(% Pr.)
FVC in L.
(% Pr.)
CF F 16 ΔF508 / ΔF508 N N N Y N N Y N 33 2.42 (90) 2.97 (100)
CF M 14 ΔF508 / ΔF508 N N N Y N N Y N 5 3.49 (112) 3.87 (106)
CF M 10 G178R / LA67P N N N Y N N N N 2 1.90 (93) 2.57 (108)
CF F 14 ΔF508 / ΔF508 N N N Y N N Y N 19 2.70 (97) 3.33 (108)
CF M 7 ΔF508 / ΔF508 N N N Y N N N N 57 1.23 (90) 1.57 (103)
CF F 14 ΔF508 / UNK N N N Y N N Y N 247 2.20 (72) 2.80 (82)
CF M 14 ΔF508 / 1898+7GNA N Y N N N N Y Y 34 2.32 (76) 2.79 (79)
CF F 32 ΔF508 / ΔF508 N N N Y N N N N 135 2.67 (81) 2.22 (78)
CF F 42 ΔF508 / 749NUCT2T N N N Y N N N N 34 2.46 (76) 3.91 (76)
CF M 15 ΔF508 / ΔF508 N N N Y N N Y Y 8 3.02 (82) 4.33 (105)
CF M 18 ΔF508 / 711 +1-G-NA N N Y Y N N N Y 1008* 4.11 (92) 3.11 (94)
CF F 14 ΔF508 / E1371X N N N Y N N N N 2 2.68 (88) 2.31(97)
CF-AC M 13 ΔF508 / ΔF508 Y Y N Y N N N N 35 2.39 (95) 2.89 (99)
CF-AC F 18 ΔF508 / ΔF508 Y Y N Y N N Y N 35 1.51 (54) 2.80 (91)
CF-AC F 15 ΔF508 / ΔF508 Y N Y N N N N N 123 2.61 (97) 3.20 (107)
CF-AC F 19 ΔF508 / ΔF508 Y N Y Y N N N N 18 2.56 (96) 3.11 (107)
CF-AC F 22 ΔF508 / ΔF508 Y N N Y N N Y N 40 3.09 (101) 3.69 (98)
CF-AC M 17 ΔF508 / ΔF508 Y Y Y Y N N N N 39 3.30 (85) 4.06 (92)
CF-AC M 20 ΔF508 / 1717-1‐G-NA Y N Y N Y N N Y 204 4.11 (92) 4.96 (94)
CF-AC F 30 ΔF508 / ΔF508 Y N N Y Y N Y Y 34 2.75 (83) 3.73 (96)
CF-AC F 46 W1282X / W1282X Y N N Y N N Y N 44 2.83 (101) 3.63 (104)
CF-AC M 26 ΔF508 / ΔF508 Y Y Y Y N N Y N 8.4 3.83 (81) 5.97 (103)
CF-AC F 14 ΔF508 / ΔF508 Y Y Y N N N N N 35 1.62 (67) 2.13 (79)
CF-AC F 33 ΔF508 / ΔF508 Y Y Y Y N N Y N 181 1.27 (37) 2.31 (56)
CF-AC M 51 ΔF508 / ΔF508 Y Y Y N N N Y N 2 2.60 (94) 4.10 (90)
CF-AC F 51 ΔF508 / ΔF508 Y Y Y N N N Y N 5 2.84 (55) 3.95 (76)
CF-ABPA F 18 ΔF508 / W1282X Y N N Y N N N N 1417 2.84 (55) 3.95 (76)
CF-ABPA M 28 ΔF508 / ΔF508 N Y Y N Y N N N 1016 2.84 (55) 3.95 (76)
CF-ABPA M 38 ΔF508 / 7711-G-NT Y N N Y Y Y Y Y 571 0.98 (39) 1.57 (50)
CF-ABPA M 19 ΔF508 / ΔF508 Y N Y N N N N N 1204 1.94 (43) 4.30 (70)
CF-ABPA F 17 ΔF508 / ΔF508 Y N N N N Y Y Y 211** (24) 3.03 (108) 3.41 (111)
CF-ABPA F 16 ΔF508 / R334W N N Y N Y N Y Y 1162 1.38 (48) 2.27 (72)
CF-ABPA F 11 G542X / C1811+1643GNT, 7T/9T poly T Y N N Y N N Y N 1932 0.73 (42) 1.37 (69)
CF-ABPA M 8 ΔF508 / 3272-28ANG, 7T/9T poly T N Y Y Y Y N N N 1162 1.63 (37) 2.35 (44)
CF-ABPA M 69 ΔF508 / 6194V, 7T/9T N Y N Y N N Y N 522 1.44 (54) 2.35 (52)
CF-ABPA M 21 ΔF508 / ΔF508 N Y Y Y Y Y Y N 1030 1.16 (27) 3.08 (60)
CF-ABPA M 9 ΔF508 / ΔF508 N N Y Y N Y Y Y 1106 1.19 (98) 1.65 (120)
CF omalizumab F 11 3849+10kbCNT / UNK Y N Y N N Y Y Y 775 2.21 (56) 3.53 (76)
CF omalizumab M 11 ΔF508 / ΔF508 Y N N Y N Y N N 948 1.33 (54) 54 (78)
Af, A. fumigatus; F, female; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; IgE, immunoglobulin E; ITRA, itraconazole; M, male; med,
medication; MPA, mucoid P. aeruginosa; patients OS, oral steroids; PA, P. aeruginosa (non‐mucoid); Pr., Predicted; SA, S. aureus; TOBI, inhaled tobramycin; ZIT,
zithromax. *This patient is atopic and has many environmental allergies. He presents hives and ichty eyes anytime he is exposed to following allergens: rye grass
(specific IgE: 14.5 Ku/L) and/or timothy grass (specific IgE: 38.8 Ku/L) and/or cat dander (specific IgE: 37.6 Ku/L) and/or dust mite (specific IgE: N100 Ku/L)].
**This patient had a clinically stable (annual evaluation) baseline IgE level of 24 Ku/L increasing to 211 Ku/L when she had a pulmonary exacerbation unresponsive
to specific antibiotherapy with other criteria for acute ABPA.
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and uncertain impact on the course of the disease [8–10]. In
others, ABPA occurs, which severely impacts lung function [11].
The reasons underlying the progression from CF-AC to
CF-ABPA are unknown but host genetic factors are likely to be
involved [12,13]. Over the last two decades, cases of CF-AC and
CF-ABPA have become increasingly prevalent [5,7,14]. Fifteen
to 60% of all CF patients are colonized by Af and an additional
10% of CF patients have ABPA [4,6,7].
Despite the increasing prevalence of AC and ABPA in CF,
the distinction of CF-ABPA from CF-AC is often difficult
[5,15], since it is typically made after the exclusion of bacterial
exacerbations as a cause of clinical deterioration, and involves
the complex employment of serologic and imaging criteria [16].Although inflammation in CF is characterized by blood and
airway neutrophilia [2], ABPA is defined by a strong immuno-
globulin (Ig) E-mediated allergic component. Consistent with this
the allergic mediator histamine is reportedly increased in blood
from ABPA patients [17]. Since histamine in blood is mostly
released by basophils, we hypothesized that blood basophils may
be activated in patients with CF-ABPA.
Although blood basophils representb1% of blood leukocytes,
flow cytometry can easily analyze this rare subpopulation. Blood
basophils constitutively express the surface interleukin (IL)-3
receptor CD123. Upon specific allergen activation, two further
markers, CD63 (a tetraspanin intracellular granule marker) and
CD203c (an ecto-nucleotide pyrophosphatase/phosphodiester-
ase) are upregulated on the surface of basophils [18]. CD63 was
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and utilization of flow cytometry for monitoring allergen-specific
IgE-mediated activation of basophils. More recently, CD203c
was identified but its mechanism of expression has not yet been
fully elucidated [20]. CD203c is expressed constitutively and
increases markedly upon specific activation of blood basophils in
patients with atopic diseases such as asthma [21], food allergy
[22,23], drug allergy [24] and allergy to Hymenoptera venoms
[25].
In this study, we found that CF-ABPA patients, when
compared to both CF-AC and CF patients, display characteristic
increases in blood basophil CD203c levels at baseline and
following ex vivo stimulation with an Af allergenic extract or with
recombinant Asp f1, a major Af allergen [26]. CD123 levels
tended to be low in blood basophils from CF-ABPA patients at
baseline and after activation, while CD63 levels were similar in
the three groups. Plasma Thymus and Activation-Regulated
Chemokine (TARC, a.k.a. CCL17) and plasma supernatant
levels of histamine after basophil activation were similar in the
three groups of patients.2. Methods
2.1. Patients
We studied 39 patients, including 12 CF patients, 14 CF-AC
patients, 11 CF-ABPA patients and 2 CF-ABPA patients
treated with omalizumab (Table 1). The Stanford Administra-
tive Panel of Human Subjects in Medical Research approved
this study. All 39 CF subjects (or parents, for minors) signed
informed consents before they underwent study procedures.
Diagnosis of CF was by documented sweat chloride
(N60 mmol/L by quantitative iontophoresis test) and/or one or
more clinical features consistent with CF and/or preexisting
documentation of two known CFTR mutations. CFTR geno-
type was confirmed on all subjects using the Elucigene CF29
assay (Tepnel Molecular Diagnostics, Abingdon, Oxon, UK).
CF-AC was defined as the presence of Af in ≥2 differentFig. 1. Surface CD203c, CD63 and CD123 levels in blood basophils at baseline in
and 75th percentiles, with median line and whiskers respresenting 10th and 90th p
(N=12, light grey) patients, CF-AC (N=12, dark grey), CF-ABPA (N=11, black).
Non-significant differences are omitted.sputum cultures within the past two years. One CF-AC had
Aspergillus bronchitis (Table 1, patient 24) [10]. The diagnosis
of CF-ABPA was made using published CF Foundation
Consensus Conference criteria modified to include markedly
increased IgE over prior stable baseline [16,27]. Total blood
IgE levels were measured using the Immunocap (Phadia,
Portage, MI, USA) assay.
2.2. Sample collection
Blood was collected by venipuncture in EDTA Vacutainer
tubes (BD Biosciences, San Jose, CA) and immediately placed on
melting ice.Within 30 minutes, blood was centrifuged at 400 G for
10 minutes at 4 °C to separate the erythrocyte/leukocyte pellet
(kept on melting ice) from platelet-rich plasma. Platelet-rich
plasma was further spun at 3000 G for 10 minutes at 4 °C to
remove platelets and yield platelet-free plasma. 400 μl of “baseline
plasma” were kept at −80 °C, for TARC measurement (see
below). The erythrocyte/leukocyte pellet was reconstituted to its
original volume with platelet-free plasma, yielding platelet-free,
reconstituted blood. We used platelet-free reconstituted blood to
assess blood basophil function, so as to avoid platelet-triggered
aggregation and clotting in the course of the 10- and 30-minute,
37 °C incubation with saline or extracts.
2.3. Incubation with saline or extracts
We assessed blood basophil characteristics under 5 condi-
tions: (i) on ice, at baseline; (ii) upon incubation with phosphate-
buffered saline (PBS) as a nonimmunogenic control; (iii-iv) upon
incubation with Af extract or rAsp f1; and (v) upon incubation
with a non-offending (peanut) allergen extract as an immuno-
genic control. Clinical grade Af and peanut skin test allergen
extracts were from Greer Laboratories (Lenoir, NC, USA).
rAsp f1 was obtained from Indoor Biotechnologies Inc.
(Charlottesville, VA, USA). For each of the three types of
incubation [conditions (ii), (iii-iv) and (v) listed above], 100 μl of
platelet-free, reconstituted blood, was mixed with either 3 μl ofCF-ABPA, CF-AC and CF patients. Shown are box plots (delimited by 25th
ercentiles) for CD203c, CD63 and CD123 levels in blood basophils from CF
Differences between groups were evaluated with the Wilcoxon rank-sum test.
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Incubations were stopped by adding ice-cold PBS with EDTA
(2.5 mM final) and cells were pelleted by centrifugation (490 G,
5 minutes, 4 °C) for surface staining. Supernatants were kept at
−80 °C for histamine measurement (see below).2.4. TARC measurement by ELISA
TARC (CCL17) levels were measured in duplicate in plasma
samples collected at baseline by sandwich ELISA (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer's in-
structions. TARC concentrations were calculated from standard
curves with detection limits of 16–2,000 pg/mL.Fig. 2. Surface CD203c levels in blood basophils upon ex vivo stimulation with
plots for CD203c levels in blood basophils from CF (N=12, light grey), CF-AC (N=
30 minute (bottom) allergen stimulation. Differences between groups were evalu
stimulations within each group were evaluated with the Wilcoxon signed-rank test.2.5. Histamine measurement by mass spectrometry
Histamine levels were measured in supernatants from
stimulated blood basophil samples using the commercially
available EZ:faast amino acid analysis kit (Phenomenex,
Torrance, CA, USA).
2.6. Flow cytometric analysis
Aliquots of blood from study patients were characterized
using surface staining combinations for flow cytometric analysis
[29] at baseline and 10 and 30 minutes after activation. Surface
staining for CD203c, CD63 and CD123 was performed prior to
fixation as described elsewhere (see [28]). Data was acquiredAf (offending) or peanut (non-offending) allergen extracts. Shown are box
14, dark grey) and, CF-ABPA (N=11, black) patients upon 10-minute (top) and
ated with the Wilcoxon rank-sum test. Differences between Af and peanut
Non-significant differences are omitted.
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with 4 lasers (535, 488, 633, 405 nm), 2 light scatter detectors and
18 fluorescent detectors and exported for compensation and
analysis using FlowJo (Treestar, Ashland, OR, USA).
2.7. Standardization of flow cytometry data acquisition
To limit day-to-day variability, antibodies were purchased in
large batches, titrated and used at saturating concentrations
throughout the study. To provide fluorescence background
quantification in measurement channels, one aliquot of each
sample was ƒstained with the fixable viability dye but left
unstained in other channels (fluorescence minus one -FMO-
background control aliquots). To standardize signal output by
the flow cytometer, a daily laser calibration and an additional
fluorescence detector calibration procedure using a standard set
of multicolor fluorescence beads was run. All MFI results were
normalized to MFI from standard beads run at the beginning
and end of each FACS session.
2.8. Statistics
We used JMP9 (SAS Institute, Cary, NC, USA) for all
statistical analyses presented here. For between- and within-
group comparisons, we used the nonparametric Wilcoxon rank-
sum and signed-rank tests, respectively. Differences were
considered significant with Pb .05.
3. Results
3.1. Basophil CD203c levels are increased at baseline in
patients with CF-ABPA
We used flow cytometry and a sequential gating method to
discriminate live basophils from other populations of cells
found in blood. We found that basophil CD203c levels at
baseline (measured as median fluorescence intensity, MFI)
were significantly increased in CF-ABPA compared to CF-AC
and CF patients (Fig. 1; 12 CF patients, 13 CF-AC patients and
11 CF-ABPA patients, P= .02 between CF-ABPA and CF-AC
patients, and P= .003 between CF-ABPA and CF patients,
respectively). Baseline levels for CD63 and CD123 did not
differ between the three groups. Note that baseline data from
patients 19 and 23 (Table 1) were not deemed robust enough
due to the very low number (b300) of basophils in the
corresponding baseline aliquots.
3.2. Ex vivo stimulation with Af extract markedly increases blood
basophil CD203c levels in CF-ABPA compared to CF-AC and
CF patients
Af extract stimulation for 10 minutes induced markedly higher
increases of blood basophil CD203c levels in CF-ABPA patients
than in either CF-AC (+251%, P=.001) or CF (+390%,
P=.0002) patients (Fig. 2). By contrast, after stimulation with a
non-offending peanut allergen extract , basophils fromCF-ABPA,
CF-AC, or CF patients did not exhibit significant differences insurface levels of CD203c; this was determined by both within-
group (peanut extract stimulation vs. no stimulation for each
patient/subject) and between-group (peanut extract stimulation in
CF-ABPA vs. CF-AC, or CF-ABPA vs. CF) comparisons.
CD203c upregulation was seen in basophils from the CF-AC
group following stimulation with the Af extract compared to
stimulation with the peanut extract (P=.0133). After a more
prolonged exposure with Af extract stimulation for 30 minutes, we
also observed highly significant increases in surface levels of
CD203c in blood basophils from CF-ABPA patients compared to
CF-AC (P=.02) and CF patients (P=.0001), although the
distinction between CF-ABPA and CF-AC was not as significant
as that seen at 10 minutes (Fig. 2). Three CF (#1, 2 and 6, Table 1)
and 3 CF-AC (#16, 18 and 22, Table 1) were sensitized to Af
(positive Af-specific IgE); four did not react in the basophil assay
while 2 (#6 and 18) did. The 10 minute activation CD203c
activation assay yielded areas under the ROC curves of .91 for CF-
ABPA vs CF-AC (p=0.0002) and .97 for CF-ABPA vs CF
(pb0.0001).3.3. Blood basophil CD63 and CD123 levels remain largely
unchanged in the three groups of CF patients following an ex
vivo stimulation with Af extract
As shown in Fig. 3 (top panels), there were no differences in
CD63 levels of stimulated blood basophils in between-group
comparisons. However, within-group comparisons showed that
10-minute stimulation with Af extract significantly increased
blood basophil CD63 levels in CF-ABPA and CF-AC patients
compared to the stimulation with the non-offending allergen
control peanut extract (P=.008 and P=.014 within CF-ABPA and
CF-AC groups, respectively). Ex vivo stimulation with Af extract
tended to decrease the level of CD123 on the surface of blood
basophils in patients with CF-ABPA and CF-AC compared to CF
patients (between-group comparisons), but these differences were
not statistically significant at either 10- or 30-minute timepoints
(data not shown). There were no differences in CD123 levels on
the surface of basophils after stimulation with Af as compared to
peanut extract in within-group comparisons.3.4. Plasma TARC (CCL17) levels at baseline and supernatant
histamine levels upon stimulation do not distinguish CF-ABPA
from CF-AC and CF patients
Unlike blood basophil CD203c levels, plasma TARC (CCL17)
levels measured by ELISA were similar in the three patient groups
(Fig. 3 panel A). We also determined the level of histamine release
in the supernatant fraction of blood basophil samples following Af
or peanut allergen stimulation. To this end, we developed a highly
sensitive mass spectrometry method capable of detecting changes
in histamine levels occurring upon 10- to 30-minute ex vivo
allergen stimulation within experimental aliquots of 100 μl of
blood. Af allergen stimulation did not result in any significant
difference in supernatant histamine release between the three
groups (Fig. 3 panel B).
Fig. 3. Plasma TARC (CCL17) and supernatant histamine measurements in samples from patients with CF, CF-AC and CF-ABPA. (A) Shown are box plots for
baseline TARC levels in plasma fromCF (N=11, light grey), CF-AC (N=13, dark grey), andCF-ABPA (N=11, black) patients. Therewere no significant differences inwithin-
and between-group analyses. (B) Shown are mean and standard deviation for histamine levels in blood aliquots from CF (N=8, light grey), CF-AC (N=8, dark grey), and CF-
ABPA (N=9, black) patients upon 10-minute (top panels) and 30 minute (bottom panels) allergen stimulation. There were no significant differences in within- and between-
group analyses.
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Fig. 4. Activation of blood basophils from patients with CF-ABPA following ex vivo stimulation with rAsp f1. (A) Shown are box plots for surface CD203c
levels in blood basophil following ex vivo stimulation for 30 minutes with rAsp f1 in CF (N=9, light grey), CF-AC (N=10, dark grey) and, CF-ABPA patients (N=8,
black). (B) Titration of the antigen rAsp f1 at 10-minute (top panel) and 30-minute (bottom panel) of stimulation. Shown are histograms for CD203c surface
expression in a representative subject with CF-ABPA.
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significant increase in blood basophil CD203c levels in CF-ABPA
compared to CF-AC and CF patients
rAsp f1 is a major 18 kDa Aspergillus fumigatus allergen and a
member of themitogillin family of cytotoxins (26). Consistent with
the results obtained with the Af extract (which contains a complex
mixture of allergens), rAsp f1 also elicited amarked upregulation of
CD203c on basophils from CF-ABPA patients (P=.02 between
CF-ABPA and CF-AC patients, Fig. 4). However, peak upregula-
tion was seen at the 30 minute rather than the 10 minute time point
(shown are results using 2 ng/mL rAsp f1 stimulation, Fig. 4). A
dose–response relationship was observed, whereby increasing
amounts of rAsp f1 elicited greater upregulation of blood basophil
CD203c levels.4. Discussion
In this study we found that CF-ABPA patients, as compared to
both CF-AC and CF patients, display increases in blood basophil
CD203c levels both at baseline and following 10- or 30-minute ex
vivo stimulation with Af extract and/or recombinant Asp f1. CD123
levels tended to be low in blood basophils fromCF-ABPA patients
at baseline and upon activation. CD63 levels remained largely
unchanged, except for an upregulation in CF-ABPA and CF-AC
groups after 10-minute stimulation (within-group comparisons).
Plasma TARC/CCL17 levels were not elevated in CF-ABPA.
After allergen stimulation of basophils, histamine levels in the
plasma supernatant remained very low and similar among the three
categories of CF patients.
An increase in blood basophil CD203c levels at baseline has
been reported in patients with other atopic diseases such as
asthma [21], urticaria [30] and food allergy [29]. CD203c is a
transmembrane ectoenzyme that is upregulated on the surface
of basophils following allergen-specific activation [19,22,23].
The upregulation of this enzyme at the surface of basophils can be
IgE-mediated [20]. In two CF-ABPA patients undergoing
treatment with omalizumab the increase of CD203c following
ex vivo stimulation was completely inhibited (data not shown).
The upregulation of basophil CD203c thus appears to be partially,
but perhaps not exclusively, IgE-mediated. Further experiments
featuring more patients at baseline and after various timepoints
and doses of omalizumab are needed to clarify this potential
therapeutic effect.
The distinction of CF-ABPA from CF-AC remains highly
challenging in the clinic, despite the consensus revision of the
classic ABPA diagnostic criteria for CF patients published in 2003
[16]. The diagnosis of ABPA (and CF-ABPA) remains dependent
upon a constellation of clinical, laboratory and radiological
components, several of which (e.g., assay for Af precipitins or IgG
antibodies) are not standardized [16]. Several groups have
attempted to identify biomarkers that could more easily identify
ABPA in CF patients, but this quest has remained inconclusive so
far [15,31,32]. For example, TARC levels have been reported to
be increased in blood from patients with CF-ABPA, particularly
during exacerbation [15,32], but this finding has not beenreproduced [33]. We did not observe differences in plasma
TARC between CF-ABPA, CF-AC and CF groups.
Other investigators have suggested that histamine may be
increased in blood from ABPA patients [17]. In our assay,
however, histamine levels in the plasma supernatant fraction of ex
vivo allergen-stimulated blood basophils were not increased in the
CF-ABPA group despite basophil surface marker changes. This
discrepancy might be explained by the fact that microvolumes of
blood are used in our assay (100 μL of blood per condition),
which may hamper the measurement of a significant change in
histamine levels. Alternatively, histamine is known to not only be
released by basophils but also by neutrophils, eosinophils and
platelets [34], all of which were not activated in the conditions of
our assay (data not shown).
Several investigators have employed immunoassays using
purified or recombinant major Af antigens such as Asp f1, Asp
f2, Asp f4 and Asp f6. Whereas Asp f4, an endocellular protein
of unknown function, and Asp f6, a manganese-dependent
superoxide dismutase, are commonly associated with ABPA,
Asp f1 was shown to be less specific but highly sensitive for
Aspergillus-allergic patients [31,35]. In our assay, blood basophil
CD203c expression was greater following ex vivo stimulation
with rAsp f1 in patients with CF-ABPA than in CF-AC and CF
patients, indicating that it may have utility as a standardized
allergen in a potential clinical test. As two of 6 Af-sensitized
patients without ABPA were positive in the CD203c assay long-
term longitudinal data will be required to see if such patients
develop ABPA over time. Analogously, one non-sensitized
CF-AC patient (#25, Table 1) showed a positive response. Thus,
some overlap of CD203c levels between a few CF-ABPA and
CF-AC or CF patients was observed and so it is premature to assert
that our assay may serve as a diagnostic test for CF-ABPAwithout
longitudinal studies in larger and diversely sourced patient
samples, and further analysis of positive predictive value, negative
predictive value, sensitivity, specificity and threshold.
In conclusion, whereas CF is usually associated with
pulmonary inflammation involving mostly neutrophils in airways
and lymphocytes in airway walls [36], its ABPA complication
involves a systemic allergic component that includes priming and
hyper-responsiveness of blood basophils to Af allergens.
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